Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

KSC reported for 2023 by IFRS

4/27/24 KTSB

Yakovlev reported for 2023 by IFRS

4/27/24 IRKT

TNS Energo Nizhny Novgorod reported for 3 months of 2024 under RAS

4/27/24 NNSB

Polyus reported for 3 months of 2024 by RAS

4/27/24 PLZL

LSR reported for 3 months of 2024 by RAS

4/27/24 LSRG

KuibyshevAzot reported for 3 months of 2024 by RAS

4/27/24 KAZT

Ashinsky Metzavod reported for 2023 by IFRS

4/27/24 AMEZ

CZPSN reported for 2023 by RAS

4/27/24 PRFN

Belon reported for 2023 by IFRS

4/27/24 BLNG

Rosseti Kuban reported for 3 months of 2024 by RAS

4/27/24 KUBE